公开(公告)号：US20240270796A1

公开(公告)日：2024-08-15

申请号：US18494219

申请日：2023-10-25

申请人： THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.

发明人： Xinle Cui ,  Clifford M. Snapper

IPC分类号： C07K14/005 ,  A61K39/245 ,  A61K39/25 ,  A61P31/22 ,  C12N7/00

CPC分类号： C07K14/005 ,  A61K39/245 ,  A61K39/25 ,  A61P31/22 ,  C12N7/00 ,  C12N2710/16034 ,  C12N2710/16071 ,  C12N2710/16134 ,  C12N2710/16171 ,  C12N2710/16234 ,  C12N2710/16271 ,  C12N2710/16334 ,  C12N2710/16371 ,  C12N2710/16634 ,  C12N2710/16671 ,  C12N2710/16734 ,  C12N2710/16771

摘要： Provided are antigenic compositions and uses thereof that include at least two human herpesvirus (HHV) polypeptides involved in mediating HHV binding, fusion, and entry into host cells, such as gp350, gH, gL, and gB, or nucleic acids encoding the polypeptides. The two HHV polypeptides comprise any combination of: a gB polypeptide; a gp350 polypeptide; a gL polypeptide; and a gH polypeptide, and optionally any one or more of the following polypeptides: gp42, gM, gN, gl, gC, gE, gD, ORF68, BMRF-2, BDLF2, UL128, UL130, UL131A, and gpK8.1. Also disclosed are methods of inducing an immune response or treating or preventing O an HHV infection in a subject by administering to the subject at least two of the HHV polypeptides or nucleic acid(s) encoding the same. Methods of passively transferring immunity using high-titer anti-HHV antibodies or immune cells are also disclosed.

公开(公告)号：US20240269267A1

公开(公告)日：2024-08-15

申请号：US18566859

申请日：2022-06-03

申请人： The Wistar Institute of Anatomy and Biology

发明人： David Weiner ,  Pratik Bhojnagarwala ,  Ebony Gary

IPC分类号： A61K39/295 ,  A61K39/00 ,  A61P31/16 ,  A61P31/22

CPC分类号： A61K39/295 ,  A61P31/16 ,  A61P31/22 ,  A61K2039/53 ,  A61K2039/572 ,  C12N2710/16134 ,  C12N2710/16634 ,  C12N2730/10134 ,  C12N2740/13034 ,  C12N2760/16134 ,  C12N2760/18534 ,  C12N2760/20234 ,  C12N2770/24234

摘要： Disclosed herein is a composition comprising one or more viral antigen or a recombinant nucleic acid sequence that encodes one or more viral antigen with enhanced immunogenicity in vivo. Also disclosed herein is a method of generating an immune response in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating a viral infection in a subject using said composition and methods.

公开(公告)号：US12036272B2

公开(公告)日：2024-07-16

申请号：US18064168

申请日：2022-12-09

申请人： Danmarks Tekniske Universitet

发明人： Sine Reker Hadrup ,  Vibeke Mindahl Rafa ,  Søren Nyboe Jakobsen

IPC分类号： A61K39/00 ,  A61K35/17 ,  A61K39/12 ,  A61K39/145 ,  A61K39/245 ,  A61P31/16 ,  A61P31/22 ,  A61P35/00 ,  C12M1/12 ,  C12N5/00 ,  C12N5/0783 ,  C12N7/00

CPC分类号： A61K39/0011 ,  A61K35/17 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001112 ,  A61K39/001113 ,  A61K39/001114 ,  A61K39/001124 ,  A61K39/001168 ,  A61K39/001182 ,  A61K39/001195 ,  A61K39/12 ,  A61K39/145 ,  A61K39/245 ,  A61P31/16 ,  A61P31/22 ,  A61P35/00 ,  C12M25/14 ,  C12N5/0636 ,  C12N7/00 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/55527 ,  A61K2039/55533 ,  A61K2039/605 ,  A61K2039/6087 ,  A61K2039/645 ,  C12N2501/2302 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/50 ,  C12N2533/70 ,  C12N2710/16134 ,  C12N2710/16234 ,  C12N2760/16034

摘要： The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise antigens, such as peptide-MHC (pMHC) class I molecules, and specific combinations of cytokines and co-stimulatory molecules to allow effective expansion and functional stimulation of specific T cells.

公开(公告)号：US11986521B2

公开(公告)日：2024-05-21

申请号：US15734634

申请日：2019-06-07

申请人： VAKZINE PROJEKT MANAGEMENT GMBH

发明人： Bodo Plachter ,  Inessa Penner

IPC分类号： A61K39/245 ,  A61K39/00 ,  A61P31/22 ,  C07K14/005 ,  C12N7/00

CPC分类号： A61K39/245 ,  A61P31/22 ,  C07K14/005 ,  C12N7/00 ,  A61K2039/5252 ,  A61K2039/545 ,  C12N2710/16121 ,  C12N2710/16122 ,  C12N2710/16134

摘要： The present invention relates to nucleic acid molecules encoding a recombinant human cytomegalovirus (HCMV) strain, dense bodies produced by said HCMV strain and preparations of said dense bodies for use in medicine, particularly as a vaccine against HCMV.

公开(公告)号：US20240156928A1

公开(公告)日：2024-05-16

申请号：US18424395

申请日：2024-01-26

申请人： City of Hope

发明人： Xiuli Wang ,  Stephen J. Forman ,  Don J. Diamond

IPC分类号： A61K39/00 ,  A61K35/17 ,  A61K39/12 ,  A61K39/17 ,  A61K39/245 ,  A61P35/00 ,  C07K14/705 ,  C07K14/71 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

CPC分类号： A61K39/0011 ,  A61K35/17 ,  A61K39/12 ,  A61K39/17 ,  A61K39/245 ,  A61P35/00 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/71 ,  C07K16/2803 ,  C07K16/2833 ,  C12N5/0636 ,  C12N5/0637 ,  C12N5/0638 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/585 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/03 ,  C12N2501/998 ,  C12N2710/16134

摘要： T cells expressing a chimeric antigen receptor and a T cell receptor specific for CMV (bi-specific T cells) are described as a methods for using such cells in immunotherapy. In the immunotherapy methods, the recipient can be exposed to a CMV vaccine in order to expand and/or stimulate the be-specific T cells.

公开(公告)号：US20240016930A1

公开(公告)日：2024-01-18

申请号：US18354849

申请日：2023-07-19

申请人： City of Hope

发明人： Don J. Diamond ,  Xiuli Wang

IPC分类号： A61K39/395 ,  A61K35/17 ,  A61K39/285 ,  A61P31/20 ,  A61K39/12 ,  C07K14/005 ,  C07K14/00 ,  C12N15/86 ,  A61P35/00 ,  A61K39/245 ,  C07K14/725 ,  C07K14/73 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783

CPC分类号： A61K39/39558 ,  A61K35/17 ,  A61K39/285 ,  A61P31/20 ,  A61K39/12 ,  C07K14/005 ,  C07K14/00 ,  C12N15/86 ,  A61P35/00 ,  A61K39/245 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C12N5/0636 ,  C12N2710/16134 ,  C12N2710/16122 ,  C12N2710/24134 ,  C12N2710/24143 ,  A61K2039/5256

摘要： A method for treating a patient comprising: (a) providing a composition comprising a population of T cells expressing both a chimeric antigen receptor (CAR) and a T cell receptor specific for a cytomegalovirus (CMV) antigen; (b) administering the composition to the patient; and (c) administering to the patient a viral vector encoding: (i) CMV pp65 and (ii) a fusion protein comprising exon 4 of CMV protein IE1 (e4) and exon 5 of CMV protein IE2 (e5) either prior to or subsequent to administering the composition comprising a population of T cells to the patient is described.

公开(公告)号：US20230248820A1

公开(公告)日：2023-08-10

申请号：US16605238

申请日：2018-04-18

申请人： GLAXOSMITHKLINE BIOLOGICALS, S.A.

发明人： Enrico Malito ,  Sumana Chandramouli ,  Andrea Carfi ,  Matthew Bottomley

IPC分类号： A61K39/245 ,  C07K14/005 ,  A61K47/64

CPC分类号： A61K39/245 ,  C07K14/005 ,  A61K47/646 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12N2710/16152

摘要： Described are mutant, human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.

公开(公告)号：US11717568B2

公开(公告)日：2023-08-08

申请号：US17100573

申请日：2020-11-20

申请人： CITY OF HOPE

发明人： Don J. Diamond ,  Felix Wussow

IPC分类号： A61K39/245 ,  C07K14/005 ,  A61K39/12 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/245 ,  A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/70 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12N2710/24143 ,  C12N2799/023 ,  C12N2800/204

摘要： In one embodiment, an expression system for expressing a UL128 complex is provided herein. The expression system may include a bacterial artificial chromosome (BAC) construct, wherein the BAC construct comprises a viral vector inserted with a set of DNA sequences that encode a UL128 complex. In another embodiment, a vaccine composition for preventing HCMV infection is provided. The vaccine composition may include a viral or bacterial vector capable of expressing a UL128 complex and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof or additional vector expressing a protein adjuvant. The viral vector may be an MVA and the UL128 complex includes five HCMV proteins or antigenic fragments thereof: UL128, UL130, UL131A, gL, and gH. In some embodiments, the viral vector is further inserted with one or more additional DNA sequences that encode one or more additional HCMVHCMV proteins or antigenic fragments thereof such as pp65, gB or both, or such as gM/gN or gO.

公开(公告)号：US20190247500A1

公开(公告)日：2019-08-15

申请号：US16343701

申请日：2017-10-19

申请人： CITY OF HOPE

发明人： Don J. Diamond

IPC分类号： A61K39/395 ,  A61K35/17 ,  A61K39/245 ,  C07K16/28 ,  C07K14/725 ,  C12N5/0783 ,  A61P35/00 ,  C07K14/705 ,  C07K14/73

CPC分类号： A61K39/39558 ,  A61K35/17 ,  A61K39/12 ,  A61K39/245 ,  A61K39/285 ,  A61K2039/5256 ,  A61K2039/585 ,  A61P31/20 ,  A61P35/00 ,  C07K14/00 ,  C07K14/005 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K2319/03 ,  C07K2319/33 ,  C12N5/0636 ,  C12N15/86 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12N2710/24134 ,  C12N2710/24143

摘要： A method for treating a patient comprising: (a) providing a composition comprising a population of T cells expressing both a chimeric antigen receptor (CAR) and a T cell receptor specific for a cytomegalovirus (CMV) antigen; (b) administering the composition to the patient; and (c) administering to the patient a viral vector encoding: (i) CMV pp65 and (ii) a fusion protein comprising exon 4 of CMV protein IE1 (e4) and exon 5 of CMV protein IE2 (e5) either prior to or subsequent to administering the composition comprising a population of T cells to the patient is described.

公开(公告)号：US20190211064A1

公开(公告)日：2019-07-11

申请号：US16363127

申请日：2019-03-25

申请人： GLAXOSMITHKLINE BIOLOGICALS S.A.

发明人： Andrea CARFI ,  Yingxia WEN

IPC分类号： C07K14/005 ,  C12N7/00 ,  A61K39/245 ,  A61K39/12

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/55588 ,  A61K2039/572 ,  C12N7/00 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12N2710/16151

摘要： An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.